Emetic Risk According to Therapy
Table 3. Emetic Risk of Intravenous Antineoplastic Agentsa Risk
Agent High Moderate
> Carmustine > Cisplatin > Cyclophosphamide ≥ 1500 mg/m2 > Dacarbazine
> Azacitidine > Alemtuzumab > Bendamustine > Carboplatin > Clofarabine > Cyclophosphamide < 1500 mg/m2 > Cytarabine > 1000 mg/m2
Low
> Fluorouracil > Bortezomib > Cabazitaxel > Catumaxomab > Cytarabine ≤ 1000 mg/m2 > Docetaxel > Doxorubicin HCL liposome injection > Etoposide > Gemcitabine > Ixabepilone
Minimal
> 2-Chlorodeoxyadenosine > Bevacizumab > Bleomycin > Busulfan > Cetuximab > Fludarabine
> Dactinomycin > Mechlorethamine > Streptozotocin
> Daunorubicinb > Doxorubicinb > Epirubicinb > Idarubicinb > Ifosfamide > Irinotecan > Oxaliplatin
> Methotrexate > Mitomycin > Mitoxantrone > Paclitaxel > Panitumumab > Pemetrexed > Temsirolimus > Topotecan > Trastuzumab
> Pralatrexate > Rituximab > Vinblastine > Vincristine > Vinorelbine
a List is not exhaustive. b These anthracyclines, when combined with cyclophosphamide, are now designated as high emetic risk.
Table 4. Emetic Risk by Site of Radiation Therapy Risk
Radiation High Moderate Low
> Total Body Irradiation > Total Nodal Irradiation
> Upper Abdomen > Upper Body Irradiation > Half Body Irradiation
> Cranium > Craniospinal > Head and Neck > Lower Thorax Region > Pelvis
Minimal
> Extremities > Breast
